Hikma plans new clinical study over generic Advair

(Reuters) – Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline’s popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.

Source link

Be the first to comment

Leave a Reply

Your email address will not be published.